Business Context and Reporting Period
Company: Bond Laboratories, Inc. (Note: Metadata referenced "FITLIFE BRANDS, INC." but the filing text identifies the registrant as Bond Laboratories, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 1, 2008
Event: Entry into a Material Definitive Agreement and Acquisition of Assets.
Key Financial Metrics and Transaction Details
The filing details an asset purchase agreement with NDS Nutritional Products, Inc. and individuals Cory Wiedel and Ryan Zink. The consideration structure is as follows:
- Cash Payment: $700,000
- Secured Promissory Note (Fixed): $350,000 payable in 18 monthly installments at 6% annual interest.
- Secured Promissory Note (Fixed Assets): Amount equal to the book value of NDS fixed assets (value not specified in text), payable in 18 monthly installments at 6% annual interest.
- Secured Promissory Note (Inventory): Amount equal to the book value of product inventory (value not specified in text), payable in 12 monthly installments at 6% annual interest.
- Earn-out Payment: $350,000 (subject to adjustments), payable in 6 quarterly installments.
- Equity Issuance: 1,550,000 shares of unregistered Common Stock (par value $0.001).
Financial Statements: The filing states that financial statements of the acquired business and pro forma financial information will be filed by amendment following the closing date. The text contains a discrepancy noting a closing date of "November 15, 2007" in Item 9, despite the report date being October 1, 2008.
Material Changes and Acquired Business
Bond Laboratories acquired the assets, properties, and rights of NDS Nutritional Products, Inc., a wholesaler and distributor of nutritional products established in 2001. The acquired business focuses on Weight Loss, Sports Nutrition, and General Health. Key product lines include:
- Release Weight Loss (exclusive to GNC)
- Professional Muscular Development (exclusive to GNC)
- Dr. Health (exclusive to GNC)
- Infinite Labs (sold through distributors and retailers in the US, Canada, and Europe)
The company assumed certain liabilities associated with the acquisition as disclosed in the agreement.
Guidance, Risks, and Unusual Items
Forward-Looking Statements: The filing includes a cautionary note that statements regarding future operations, cash flows, and financial condition are predictive and subject to risks and uncertainties. Actual results may differ materially from projections.
Securities Exemption: The issuance of 1,550,000 shares was effected under exemptions for sales not involving a public offering (Rule 506, Section 4(2), and Section 4(6) of the Securities Act of 1933).
Data Discrepancy: Item 9 references a closing date of November 15, 2007, which conflicts with the report date of October 1, 2008. This may indicate a clerical error in the filing or a delayed reporting of a prior event.
Investor Verification Checklist
- Verify the exact closing date of the transaction given the conflict between the report date (Oct 1, 2008) and the closing date cited in Item 9 (Nov 15, 2007).
- Confirm the specific book values for the fixed assets and inventory notes, as these amounts were not disclosed in the summary text.
- Review the forthcoming amendment to this 8-K for the required financial statements of NDS Nutritional Products and pro forma financial information.
- Assess the impact of the 1,550,000 new shares on existing shareholder dilution.
- Examine the specific terms of the earn-out adjustments and the liabilities assumed in the full Asset Purchase Agreement (Exhibit 10.1).